NO301122B1 - Rekombinant-metoder til produksjon av serinproteaseinhibitorer og DNA-sekvenser for disse - Google Patents
Rekombinant-metoder til produksjon av serinproteaseinhibitorer og DNA-sekvenser for disse Download PDFInfo
- Publication number
- NO301122B1 NO301122B1 NO863182A NO863182A NO301122B1 NO 301122 B1 NO301122 B1 NO 301122B1 NO 863182 A NO863182 A NO 863182A NO 863182 A NO863182 A NO 863182A NO 301122 B1 NO301122 B1 NO 301122B1
- Authority
- NO
- Norway
- Prior art keywords
- dna sequence
- serine protease
- stated
- protease inhibitor
- dna
- Prior art date
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 138
- 239000003001 serine protease inhibitor Substances 0.000 title claims description 67
- 238000010188 recombinant method Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 86
- 101710102218 Serine protease inhibitor Proteins 0.000 claims abstract description 53
- 238000004519 manufacturing process Methods 0.000 claims abstract description 27
- 239000002299 complementary DNA Substances 0.000 claims abstract description 8
- 230000002068 genetic effect Effects 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 124
- 108020004414 DNA Proteins 0.000 claims description 94
- 102000004169 proteins and genes Human genes 0.000 claims description 73
- 235000018102 proteins Nutrition 0.000 claims description 72
- 239000013598 vector Substances 0.000 claims description 53
- 239000003112 inhibitor Substances 0.000 claims description 51
- 229940122055 Serine protease inhibitor Drugs 0.000 claims description 49
- 230000014509 gene expression Effects 0.000 claims description 38
- 150000001413 amino acids Chemical group 0.000 claims description 37
- 244000005700 microbiome Species 0.000 claims description 34
- 241000588724 Escherichia coli Species 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 27
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 19
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 16
- 239000004475 Arginine Substances 0.000 claims description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 14
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 12
- 102000012479 Serine Proteases Human genes 0.000 claims description 12
- 108010022999 Serine Proteases Proteins 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 229930182817 methionine Natural products 0.000 claims description 11
- 239000004472 Lysine Substances 0.000 claims description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 10
- 230000028327 secretion Effects 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 9
- 235000004279 alanine Nutrition 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 8
- 239000004474 valine Substances 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 6
- 210000003079 salivary gland Anatomy 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 244000063299 Bacillus subtilis Species 0.000 claims description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 3
- 241000235070 Saccharomyces Species 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract description 25
- 108091034117 Oligonucleotide Proteins 0.000 description 93
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 71
- 239000013612 plasmid Substances 0.000 description 43
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 40
- 239000012634 fragment Substances 0.000 description 35
- 108010082545 Secretory Leukocyte Peptidase Inhibitor Proteins 0.000 description 34
- 102000004002 Secretory Leukocyte Peptidase Inhibitor Human genes 0.000 description 34
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 31
- 102000035195 Peptidases Human genes 0.000 description 27
- 108091005804 Peptidases Proteins 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 23
- 108091008146 restriction endonucleases Proteins 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 239000004365 Protease Substances 0.000 description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 18
- 238000013519 translation Methods 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 238000005520 cutting process Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 15
- 108020004705 Codon Proteins 0.000 description 14
- 108010028275 Leukocyte Elastase Proteins 0.000 description 14
- 102100033174 Neutrophil elastase Human genes 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 235000019419 proteases Nutrition 0.000 description 12
- 108090000631 Trypsin Proteins 0.000 description 11
- 102000004142 Trypsin Human genes 0.000 description 11
- 239000012588 trypsin Substances 0.000 description 11
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 238000010561 standard procedure Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003591 leukocyte elastase inhibitor Substances 0.000 description 8
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 7
- 230000003362 replicative effect Effects 0.000 description 7
- 102000012410 DNA Ligases Human genes 0.000 description 6
- 108010061982 DNA Ligases Proteins 0.000 description 6
- 102100030635 Leukocyte elastase inhibitor Human genes 0.000 description 6
- 101710091916 Leukocyte elastase inhibitor Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 5
- 108090000617 Cathepsin G Proteins 0.000 description 5
- 102000004173 Cathepsin G Human genes 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 101150084750 1 gene Proteins 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010054278 Lac Repressors Proteins 0.000 description 4
- 102000016387 Pancreatic elastase Human genes 0.000 description 4
- 108010067372 Pancreatic elastase Proteins 0.000 description 4
- 206010033645 Pancreatitis Diseases 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000001322 periplasm Anatomy 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 150000003355 serines Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000014621 translational initiation Effects 0.000 description 4
- 239000002753 trypsin inhibitor Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010014561 Emphysema Diseases 0.000 description 3
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 2
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 102100037981 Dickkopf-like protein 1 Human genes 0.000 description 2
- 101710125833 Dickkopf-like protein 1 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 102000035092 Neutral proteases Human genes 0.000 description 2
- 108091005507 Neutral proteases Proteins 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 101150064785 SLPI gene Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 101150050575 URA3 gene Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 101150042295 arfA gene Proteins 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 108090001092 clostripain Proteins 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 108091006086 inhibitor proteins Proteins 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 101150087557 omcB gene Proteins 0.000 description 2
- 101150115693 ompA gene Proteins 0.000 description 2
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 241000252085 Anguilla rostrata Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000818312 Mus musculus Forkhead box protein C1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 101100494726 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pep-4 gene Proteins 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 101710110949 Protein S100-A12 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 230000002849 elastaseinhibitory effect Effects 0.000 description 1
- 230000002901 elastaselike Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 108010036927 trypsin-like serine protease Proteins 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67882284A | 1984-12-06 | 1984-12-06 | |
| US80347185A | 1985-12-02 | 1985-12-02 | |
| PCT/US1985/002385 WO1986003519A1 (en) | 1984-12-06 | 1985-12-04 | Recombinant methods for production of serine protease inhibitors and dna sequences useful for same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO863182L NO863182L (no) | 1986-08-06 |
| NO863182D0 NO863182D0 (no) | 1986-08-06 |
| NO301122B1 true NO301122B1 (no) | 1997-09-15 |
Family
ID=27102096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO863182A NO301122B1 (no) | 1984-12-06 | 1986-08-06 | Rekombinant-metoder til produksjon av serinproteaseinhibitorer og DNA-sekvenser for disse |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0205475B2 (de) |
| JP (1) | JP2683500B2 (de) |
| AT (1) | ATE108205T1 (de) |
| AU (1) | AU590238B2 (de) |
| CA (1) | CA1296273C (de) |
| DD (1) | DD253642A5 (de) |
| DE (1) | DE3587875T3 (de) |
| DK (1) | DK372086D0 (de) |
| FI (1) | FI108943B (de) |
| GR (1) | GR852940B (de) |
| HU (1) | HU204563B (de) |
| IE (1) | IE64175B1 (de) |
| IL (3) | IL95223A (de) |
| MX (1) | MX9203519A (de) |
| NO (1) | NO301122B1 (de) |
| NZ (1) | NZ214456A (de) |
| PT (1) | PT81624B (de) |
| WO (1) | WO1986003519A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291662B1 (en) | 1984-12-05 | 2001-09-18 | Amgen Inc. | Recombinant methods for production of serine protease inhibitors and DNA sequences |
| US5871956A (en) * | 1984-12-06 | 1999-02-16 | Amgen Inc. | Recombinant methods for production of serine inhibitors and DNA sequences useful for same |
| WO1986003497A1 (en) * | 1984-12-06 | 1986-06-19 | Synergen Biologicals, Inc. | Serine protease inhibitors and methods for isolation of same |
| US6132990A (en) * | 1984-12-06 | 2000-10-17 | Amgen Boulder Inc. | Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same |
| US5900400A (en) * | 1984-12-06 | 1999-05-04 | Amgen Inc. | Serine protease inhibitor analogs |
| DK4286A (da) * | 1985-01-07 | 1986-07-08 | Celltech Ltd | Fremgangsmaade til fremstilling af en metalloproteinaseinhibitor |
| DE3600571A1 (de) * | 1986-01-10 | 1987-08-06 | Gruenenthal Gmbh | Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel |
| US5278049A (en) * | 1986-06-03 | 1994-01-11 | Incyte Pharmaceuticals, Inc. | Recombinant molecule encoding human protease nexin |
| JPH0616716B2 (ja) * | 1986-10-14 | 1994-03-09 | 塩野義製薬株式会社 | 酵母におけるヒトｐｓｔｉの製造法 |
| AU8172787A (en) * | 1986-10-30 | 1988-05-25 | Synergen Biologicals, Inc. | Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same |
| GB2199582A (en) * | 1987-01-07 | 1988-07-13 | Bayer Ag | Analogues of pancreatic secretory trypsin inhibitor |
| US5851983A (en) * | 1987-12-28 | 1998-12-22 | Teijin Limited | Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology |
| ATE103930T1 (de) * | 1988-03-07 | 1994-04-15 | Ciba Geigy Ag | Modifizierte proteine. |
| US5180667A (en) * | 1988-03-07 | 1993-01-19 | Ciba-Geigy Corporation | Genes encoding eglin C mutants |
| US5223407A (en) * | 1988-08-31 | 1993-06-29 | Allelix Inc. | Excretion of heterologous proteins from e. coli |
| US5646015A (en) * | 1988-08-31 | 1997-07-08 | Astra Ab | Excretion of heterologous proteins from E. coli |
| US6869925B1 (en) * | 1992-09-09 | 2005-03-22 | Amgen Inc. | Inhibition of retrovirus infection |
| US6017880A (en) * | 1994-03-09 | 2000-01-25 | Amgen Inc. | Inhibition of retrovirus infection |
| BR9507165A (pt) * | 1994-03-23 | 1997-09-09 | Tokyo Tanase Company Limited | Inibidor da triptase clara agente terapêutico ou profilático para doenças virais processo terapêutico para doenças virais e uso da antileucoprotease |
| US5633227A (en) * | 1994-09-12 | 1997-05-27 | Miles, Inc. | Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
| SE9702401D0 (sv) | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| US7247704B2 (en) | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU577259B2 (en) * | 1982-08-13 | 1988-09-22 | Zymogenetics Inc. | Glycolytic promters for regulated protein expression protease inhibitor |
| GR79124B (de) * | 1982-12-22 | 1984-10-02 | Genentech Inc | |
| DE3247922A1 (de) * | 1982-12-24 | 1984-06-28 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten |
| WO1984003711A1 (en) * | 1983-03-25 | 1984-09-27 | Celltech Ltd | A process for the production of a protein |
| JPS60186290A (ja) * | 1983-08-10 | 1985-09-21 | チモ−ジエネテイツクス インコ−ポレ−テツド | アルフア−１−アンチトリプシンを細菌に表現させる方法 |
| US4711848A (en) * | 1984-03-14 | 1987-12-08 | Zymogenetics, Inc. | Site specific mutagenesis in alpha-1-antitrypsin |
-
1985
- 1985-12-04 HU HU86332A patent/HU204563B/hu unknown
- 1985-12-04 IL IL95223A patent/IL95223A/xx not_active IP Right Cessation
- 1985-12-04 AT AT85905953T patent/ATE108205T1/de not_active IP Right Cessation
- 1985-12-04 IL IL77227A patent/IL77227A/xx not_active IP Right Cessation
- 1985-12-04 EP EP85905953A patent/EP0205475B2/de not_active Expired - Lifetime
- 1985-12-04 DE DE3587875T patent/DE3587875T3/de not_active Expired - Lifetime
- 1985-12-04 WO PCT/US1985/002385 patent/WO1986003519A1/en active IP Right Grant
- 1985-12-04 AU AU52029/86A patent/AU590238B2/en not_active Expired
- 1985-12-05 CA CA000496992A patent/CA1296273C/en not_active Expired - Fee Related
- 1985-12-05 PT PT81624A patent/PT81624B/pt unknown
- 1985-12-05 IE IE308385A patent/IE64175B1/en not_active IP Right Cessation
- 1985-12-06 GR GR852940A patent/GR852940B/el unknown
- 1985-12-06 NZ NZ214456A patent/NZ214456A/en unknown
- 1985-12-06 DD DD28386885A patent/DD253642A5/de unknown
-
1986
- 1986-08-05 DK DK372086A patent/DK372086D0/da not_active Application Discontinuation
- 1986-08-05 FI FI863188A patent/FI108943B/fi not_active IP Right Cessation
- 1986-08-06 NO NO863182A patent/NO301122B1/no not_active IP Right Cessation
-
1990
- 1990-07-29 IL IL95223A patent/IL95223A0/xx unknown
-
1992
- 1992-06-26 MX MX9203519A patent/MX9203519A/es unknown
-
1994
- 1994-03-28 JP JP6057872A patent/JP2683500B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE3587875D1 (de) | 1994-08-11 |
| ATE108205T1 (de) | 1994-07-15 |
| PT81624B (pt) | 1987-10-20 |
| DE3587875T3 (de) | 2003-01-02 |
| IL95223A (en) | 1992-08-18 |
| AU5202986A (en) | 1986-07-01 |
| HU204563B (en) | 1992-01-28 |
| AU590238B2 (en) | 1989-11-02 |
| EP0205475B1 (de) | 1994-07-06 |
| CA1296273C (en) | 1992-02-25 |
| MX9203519A (es) | 1992-08-01 |
| DK372086A (da) | 1986-08-05 |
| IL95223A0 (en) | 1991-06-10 |
| NO863182L (no) | 1986-08-06 |
| GR852940B (de) | 1986-04-07 |
| DD253642A5 (de) | 1988-01-27 |
| IL77227A (en) | 1992-08-18 |
| EP0205475A4 (de) | 1990-06-27 |
| NZ214456A (en) | 1988-02-12 |
| JPH06315384A (ja) | 1994-11-15 |
| HUT41442A (en) | 1987-04-28 |
| FI863188A0 (fi) | 1986-08-05 |
| NO863182D0 (no) | 1986-08-06 |
| DE3587875T2 (de) | 1994-10-13 |
| PT81624A (en) | 1986-01-01 |
| EP0205475A1 (de) | 1986-12-30 |
| EP0205475B2 (de) | 2002-09-04 |
| FI863188A (fi) | 1986-08-05 |
| JP2683500B2 (ja) | 1997-11-26 |
| WO1986003519A1 (en) | 1986-06-19 |
| DK372086D0 (da) | 1986-08-05 |
| IE64175B1 (en) | 1995-07-12 |
| IE853083L (en) | 1986-06-06 |
| FI108943B (fi) | 2002-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO301122B1 (no) | Rekombinant-metoder til produksjon av serinproteaseinhibitorer og DNA-sekvenser for disse | |
| US8765910B2 (en) | Method for amidating polypeptides with basic amino acid C-terminals by means of specific endoproteases | |
| JP4243104B2 (ja) | 重要なタンパク質の細菌培養上清中への分泌のための融合タンパク質 | |
| US20060088878A1 (en) | Purification of recombinant proteins fused to multiple epitopes | |
| SK116896A3 (en) | Enhanced secretion of polypeptides | |
| NO863596L (no) | Enbakteriell metionin n-terminal peptidase. | |
| NO308667B1 (no) | FremgangsmÕte for fremstilling av fusjonsproteiner | |
| WO1991018101A1 (fr) | Procede de production d'une proteine | |
| US20160168226A1 (en) | Process for production of insulin and insulin analogues | |
| AU8172787A (en) | Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same | |
| Van Mellaert et al. | Efficient secretion of biologically active mouse tumor necrosis factor α by Streptomyces lividans | |
| KR100659671B1 (ko) | 신규한 융합단백질로부터 재조합 인슐린을 제조하는 방법 | |
| Masuda et al. | Efficient production of the C-terminal domain of secretory leukoprotease inhibitor as a thrombin-cleavable fusion protein in Escherichia coli | |
| US6291662B1 (en) | Recombinant methods for production of serine protease inhibitors and DNA sequences | |
| NO178870B (no) | Fremgangsmåte for fremstilling av modifisert Eglin B eller C samt DNA, ekspresjonsvektor og vertsmikroorganisme | |
| NO864442L (no) | Mutantkodende sekvens. | |
| PT716705E (pt) | Processo para a preparacao por recombinacao de proteinas na levedura hansenula | |
| JPS62501262A (ja) | セリンプロテア−ゼ阻害剤の生産のための遺伝子組み換え法と、同じ目的に有用なｄｎａ塩基配列 | |
| JPH0568558A (ja) | モニターペプタイドのアミノ酸配列をコードする新規なｄｎａ | |
| AU8076491A (en) | A novel vector to produce biologically important peptides | |
| JP2683500C (de) | ||
| WO1991019805A1 (en) | A novel vector to produce biologically important peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |